The Osteodontostomy & Artificial Keratoplasty Market size was estimated at USD 167.89 million in 2025 and expected to reach USD 196.31 million in 2026, at a CAGR of 16.82% to reach USD 498.76 million by 2032.

Osteodontostomy and artificial keratoplasty are specialized approaches for restoring vision in patients with severe corneal disease, ocular-surface failure, or blindness not adequately addressed by conventional corneal transplantation. Osteo-odonto-keratoprosthesis uses a patient-derived tooth-and-bone lamina to support an optical cylinder, while artificial keratoplasty encompasses prosthetic corneal devices and related implantation techniques. Their use is concentrated in highly specialized ophthalmic centers because patient selection, dental and ocular surgery, long-term surveillance, and rehabilitation must be coordinated.

The clinical landscape is shifting from isolated surgical innovation toward integrated, lifelong care. Greater attention is being given to preoperative ocular-surface stabilization, imaging and biocompatibility assessment, standardized rehabilitation, infection prevention, and management of complications such as extrusion, inflammation, glaucoma, and retinal disease. Training pathways and referral networks are also becoming more important because outcomes depend on multidisciplinary expertise rather than on the implant alone. Regulatory scrutiny increasingly emphasizes evidence quality, traceability, informed consent, and post-market monitoring for highly specialized devices and procedures.

Artificial intelligence can support, but not replace, specialist judgment in osteodontostomy and artificial keratoplasty. Potentially valuable applications include image-based assessment of corneal scarring and ocular-surface status, identification of retinal or optic-nerve limitations, risk stratification, surgical planning, and longitudinal detection of device-related changes. AI-enabled documentation and triage may also improve follow-up in geographically dispersed populations. Because datasets are limited and disease presentations are heterogeneous, deployment should use clinically validated tools, transparent performance criteria, human oversight, privacy safeguards, and prospective monitoring for bias and false reassurance.

North America has strong tertiary ophthalmology infrastructure, but access is shaped by referral pathways, reimbursement, and the concentration of surgeons with relevant experience. Europe benefits from established specialist centers and cross-border clinical collaboration, while national approval and funding systems can affect availability. Asia-Pacific combines advanced capabilities in countries such as Japan, South Korea, Australia, China, and India with substantial variation in access and training. Latin America is influenced by uneven specialist distribution and the need for referral and postoperative support. The Middle East is expanding advanced healthcare capacity in selected hubs, whereas Africa generally faces greater constraints in subspecialist availability, diagnostics, and long-term follow-up. Across all regions, sustainable programs require coordinated dentistry, ophthalmology, anesthesia, rehabilitation, and infection-control services.

ASEAN countries face varied specialist capacity and benefit from regional referral, training, and postoperative-care networks. BRICS members encompass major academic centers alongside substantial internal differences in access, regulatory pathways, and affordability. The European Union supports collaboration through shared scientific and regulatory frameworks, although national reimbursement and service organization remain important. G7 health systems generally possess advanced tertiary-care capabilities, but patient access and coverage differ by jurisdiction. GCC countries can leverage concentrated investment in specialist hospitals and international training partnerships, while NATO members show wide variation in health-system organization and clinical capacity. These groupings are most useful for understanding cooperation, infrastructure, and policy alignment rather than uniform clinical conditions.

Australia and Canada rely on concentrated tertiary referral services across large geographies. Brazil and Mexico must connect specialized urban centers with broader ophthalmic networks. China and India combine leading academic institutions with significant regional variation in access. France, Germany, Italy, Spain, and the United Kingdom have established ophthalmic expertise, with care shaped by national funding, referral, and regulatory arrangements. Japan and South Korea have advanced surgical and diagnostic capabilities supported by sophisticated hospital systems. Russia’s access is influenced by geographic scale and institutional concentration. The United States has extensive subspecialty infrastructure, while coverage, referral, and continuity of care can differ across patient populations. In every country, long-term monitoring and multidisciplinary coordination remain central to safe implementation.

Industry and clinical leaders should prioritize accredited multidisciplinary centers rather than isolated procedure capacity. Establish explicit referral criteria, including assessment of visual potential, ocular-surface status, systemic health, dental suitability, and patient ability to complete lifelong follow-up. Invest in surgeon and dentist training, standardized perioperative protocols, registries, adverse-event reporting, and structured patient education. Partnerships with hospitals, rehabilitation services, payers, and public-health authorities can improve continuity of care. Technology development should emphasize biocompatibility, optical performance, maintainability, and compatibility with imaging and monitoring. AI initiatives should begin with narrowly defined, validated use cases and retain specialist review at every consequential decision point.

This executive summary is structured as a qualitative synthesis of established clinical, technological, regulatory, and health-system considerations relevant to osteodontostomy and artificial keratoplasty. It distinguishes procedure-specific requirements from broader artificial-keratoplasty developments and interprets regional, group, and country differences through specialist capacity, referral infrastructure, regulation, reimbursement, and follow-up needs. Reliable research for this field should triangulate peer-reviewed ophthalmic literature, clinical guidelines, regulatory documentation, institutional protocols, trial records, and post-market safety evidence. Because published cohorts are often small and follow-up requirements are long, conclusions should be assessed for study design, endpoint consistency, selection bias, durability, and generalizability.

Osteodontostomy and artificial keratoplasty address difficult cases in which conventional corneal restoration may be unsuitable, but their value depends on more than device or surgical innovation. Patient selection, multidisciplinary execution, complication management, rehabilitation, and lifelong surveillance are the defining operational requirements. Regional and national differences in specialist capacity make referral networks and training partnerships essential. Leaders who combine rigorous evidence generation with coordinated clinical pathways, responsible digital tools, and transparent safety monitoring will be better positioned to improve access while protecting patient outcomes.